Prevalence and risk factors associated with colonization and infection of extensively drug-resistant Pseudomonas aeruginosa: A systematic review

Expert Review of Anti-Infective Therapy

Volumn 13, Issue 9, 2015, Pages 1159-1170

  Buhl, Michael ^a   Peter, Silke ^a   Willmann, Matthias ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

acquisition; colonization; extensive drug resistance; extensively drug resistant; infection; prevalence; Pseudomonas aeruginosa; review; risk factors

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; CARBAPENEM; CEPHALOSPORIN; COTRIMOXAZOLE; MONOBACTAM DERIVATIVE; PENICILLIN DERIVATIVE; PHOSPHONIC ACID DERIVATIVE; POLYMYXIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM ISOLATE; DISEASE ASSOCIATION; DRUG EFFECT; ENVIRONMENTAL FACTOR; HUMAN; INFECTION RISK; MEDICAL DEVICE; NONHUMAN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; TREND STUDY; ANIMAL; BACTERIAL COUNT; DRUG EFFECTS; MULTIDRUG RESISTANCE; PHYSIOLOGY; PREVALENCE; PROCEDURES; PSEUDOMONAS INFECTIONS;

ANIMALS; ANTI-BACTERIAL AGENTS; COLONY COUNT, MICROBIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; PREVALENCE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RISK FACTORS;

EID: 84939180144     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2015.1064310     Document Type: Review

References (85)

1. Trecarichi EM, Pagano L, Candoni A, et al. Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: an Italian multicentre prospective survey. Clin Microbiol Infect 2014; 21 (4): 337-43
2. Ruhnke M, Arnold R, Gastmeier P. Infection control issues in patients with haematological malignancies in the era of multidrug-resistant bacteria. Lancet Oncol 2014; 15 (13): e606-19
3. Ciofi Degli Atti M, Bernaschi P, Carletti M, et al. An outbreak of extremely drug-resistant Pseudomonas aeruginosa in a tertiary care pediatric hospital in Italy. BMC Infect Dis 2014; 14: 494-4
4. Pendleton JN, Gorman SP, Gilmore BF. Clinical relevance of the ESKAPE pathogens. Expert Rev Anti Infect Ther 2013; 11 (3): 297-308
5. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48 (1): 1-12
6. Sader HS, Jones RN. Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilli. Int J Antimicrob Agents 2005; 25 (2): 95-109
7. Paterson DL, Doi Y. A step closer to extreme drug resistance (XDR) in gram-negative bacilli. Clin Infect Dis 2007; 45 (9): 1179-81
8. Falagas ME, Koletsi PK, Bliziotis IA. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J Med Microbiol 2006; 55 (Pt 12): 1619-29
9. Falagas ME, Karageorgopoulos DE. Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among Gram-negative bacilli: need for international harmonization in terminology. Clin Infect Dis 2008; 46 (7): 1121-2
10. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18 (3): 268-81
11. Gomez-Zorrilla S, Camoez M, Tubau F, et al. Antibiotic pressure is a major risk factor for rectal colonization by multidrug-resistant Pseudomonas aeruginosa in critically ill patients. Antimicrob Agents Chemother 2014; 58 (10): 5863-70
12. Pena C, Gomez-Zorrilla S, Suarez C, et al. Extensively drug-resistant Pseudomonas aeruginosa: risk of bloodstream infection in hospitalized patients. Eur J Clin Microbiol Infect Dis 2012; 31 (10): 2791-7
13. Pena C, Gomez-Zorrilla S, Oriol I, et al. Impact of multidrug resistance on Pseudomonas aeruginosa ventilator-Associated pneumonia outcome: predictors of early and crude mortality. Eur J Clin Microbiol Infect Dis 2013; 32 (3): 413-20
14. ECDC. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal. for interim standard definitions for acquired resistance. Available from: http://ecdc.europa.eu/en/activities/diseaseprogrammes/ARHAI/Pages/public-consultation-clinical-microbiology-infection-article.aspx. [Last accessed 20 March 2015]
15. ECDC. Antimicrobial resistance surveillance in Europe 2013. Stockholm; 2014
16. CDC. Antibiotic Resistance Threats in the United States 2013. Atlanta; 2013
17. Sievert DM, Ricks P, Edwards JR, et al. Antimicrobial-resistant pathogens associated with healthcare-Associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 2013; 34 (1): 1-14
18. CDC. Exploring Regional Patterns of Antibiotic Resistant Healthcare-Associated Infections. Philadelphia; 2015 Available from: https://idsa.confex.com/idsa/2014/webprogram/Paper44007.html.
19. Jean S-S, Hsueh P-R, Lee WS, et al. Nationwide surveillance of antimicrobial resistance among non-fermentative Gram-negative bacteria in Intensive Care Units in Taiwan: SMART programme data 2005. Int J Antimicrob Agents 2009; 33 (3): 266-71
20. Morrissey I, Hackel M, Badal R, et al. A review of ten years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011. Pharmaceuticals (Basel) 2013; 6 (11): 1335-46
21. England PH. Voluntary surveillance of bacteraemia caused by Pseudomonas spp., Stenotrophomonas maltophilia and closely related species, England, Wales and Northern Ireland: 2013. Atlanta; 2014. Available from: https://www.gov.uk/government/publications/pseudomonas-spp-And-stenotrophomonas-spp-voluntary-surveillance-2013
22. Antiinfectives Intelligence Gesellschaft für klinisch-mikrobiologische Forschung und Kommunikation mbH. Rheinbach; 2014. Available from: http://www.bvl.bund.de/SharedDocs/Downloads/08-PresseInfothek/Germap-012.pdf?-blob=publicationFile&v=2
23. Farrell DJ, Flamm RK, Sader HS, Jones RN. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. hospitals (2011-2012). Antimicrob Agents Chemother 2013; 57 (12): 6305-10
24. Farrell DJ, Sader HS, Flamm RK, Jones RN. Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012). Int J Antimicrob Agents 2014; 43 (6): 533-9
25. Pfaller MA, Jones RN. A review of the in vitro activity of meropenem and comparative antimicrobial agents tested against 30,254 aerobic and anaerobic pathogens isolated world wide. Diagn Microbiol Infect Dis 1997; 28 (4): 157-63
26. Karlowsky JA, Jones ME, Thornsberry C, et al. Stable antimicrobial susceptibility rates for clinical isolates of Pseudomonas aeruginosa from the 2001-2003 tracking resistance in the United States today surveillance studies. Clin Infect Dis 2005; 40 (Suppl 2): S89-98
27. Croughs PD, Li B, Hoogkamp-Korstanje JA, Stobberingh E Thirteen years of antibiotic susceptibility surveillance of Pseudomonas aeruginosa from intensive care units and urology services in the Netherlands. Eur J Clin Microbiol Infect Dis 2013; 32 (2): 283-8
28. Lagace-Wiens PR, Adam HJ, Low DE. (et al): Trends in antibiotic resistance over time among pathogens from Canadian hospitals: results of the CANWARD study 2007-11. J Antimicrob Chemother 2013; 68 (Suppl (1): i23-9
29. Master RN, Clark RB, Karlowsky JA, et al. Analysis of resistance, cross-resistance and antimicrobial combinations for Pseudomonas aeruginosa isolates from 1997 to 2009. Int J Antimicrob Agents 2011; 38 (4): 291-5
30. Gentry CA, Williams RJ 2nd. Increased antimicrobial susceptibility rates for Pseudomonas aeruginosa bloodstream isolates across the Veterans Affairs Healthcare System. Diagn Microbiol Infect Dis 2015; 82 (3): 215-21
31. Bertrand X, Dowzicky MJ. Antimicrobial susceptibility among gram-negative isolates collected from intensive care units in North America, Europe, the Asia-Pacific Rim, Latin America, the Middle East, and Africa between 2004 and 2009 as part of the Tigecycline Evaluation and Surveillance Trial. Clin Ther 2012; 34 (1): 124-37
32. Slekovec C, Robert J, Trystram D, et al. Pseudomonas aeruginosa in French hospitals between 2001 and 2011: back to susceptibility. Eur J Clin Microbiol Infect Dis 2014; 33 (10): 1713-17
33. Hombach M, Wolfensberger A, Kuster SP, Bottger EC. Influence of clinical breakpoint changes from CLSI 2009 to EUCAST 2011 antimicrobial susceptibility testing guidelines on multidrug resistance rates of Gram-negative rods. J Clin Microbiol 2013; 51 (7): 2385-7
34. EUCAST. Breakpoint tables for interpretation of MICs and zone diameters Version 5.0, valid from 2015-01-01. EUCAST, Växjö; 2015
35. CLSI. M100-S23 Performance Standards for Antimicrobial Susceptibility Testing. CLSI, Wayne; 2013
36. Sader HS, Farrell DJ, Castanheira M, et al. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12). J Antimicrob Chemother 2014; 69 (10): 2713-22
37. Vettoretti L, Floret N, Hocquet D, et al. Emergence of extensive-drug-resistant Pseudomonas aeruginosa in a French university hospital. Eur J Clin Microbiol Infect Dis 2009; 28 (10): 1217-22
38. Durante-Mangoni E, Andini R, Agrusta F, et al. Infective endocarditis due to multidrug resistant gram-negative bacilli: Single centre experience over 5 years. Eur J Intern Med 2014; 25 (7): 657-61
39. Edelstein MV, Skleenova EN, Shevchenko OV, et al. Spread of extensively resistant VIM-2-positive ST235 Pseudomonas aeruginosa in Belarus, Kazakhstan, and Russia: a longitudinal epidemiological and clinical study. Lancet Infect Dis 2013; 13 (10): 867-76
40. Woodford N, Turton JF, Livermore DM. Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance. FEMS Microbiol Rev 2011; 35 (5): 736-55
41. Cabot G, Ocampo-Sosa AA, Tubau F, et al. Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study. Antimicrob Agents Chemother 2011; 55 (5): 1906-11
42. Cabot G, Ocampo-Sosa AA, Dominguez MA, et al. Genetic markers of widespread extensively drug-resistant Pseudomonas aeruginosa high-risk clones. Antimicrob Agents Chemother 2012; 56 (12): 6349-57
43. Mulet X, Cabot G, Ocampo-Sosa AA, et al. Biological markers of Pseudomonas aeruginosa epidemic high-risk clones. Antimicrob Agents Chemother 2013; 57 (11): 5527-35
44. Breathnach AS, Cubbon MD, Karunaharan RN, et al. Multidrug-resistant Pseudomonas aeruginosa outbreaks in two hospitals: association with contaminated hospital waste-water systems. J Hosp Infect 2012; 82 (1): 19-24
45. Vincenti S, Quaranta G, De Meo C, et al. Non-fermentative gram-negative bacteria in hospital tap water and water used for haemodialysis and bronchoscope flushing: Prevalence and distribution of antibiotic resistant strains. Sci Total Environ 2014; 499: 47-54
46. Kadri SS, Hohmann SF, Orav EJ, et al. Tracking colistin-treated patients to monitor the incidence and outcome of carbapenem-resistant gram-negative infections. Clin Infect Dis 2015; 60 (1): 79-87
47. Goncalves Pereira S, Marques M, Pereira J, Cardoso O. Multidrug and extensive drug resistance in Pseudomonas aeruginosa clinical isolates from a portuguese central hospital: 10-year survey. Microb Drug Resist 2014; 21 (2): 194-200
48. Patel SJ, Oliveira AP, Zhou JJ, et al. Risk factors and outcomes of infections caused by extremely drug-resistant gram-negative bacilli in patients hospitalized in intensive care units. Am J Infect Control 2014; 42 (6): 626-31
49. Kiddee A, Henghiranyawong K, Yimsabai J, et al. Nosocomial spread of class 1 integron-carrying extensively drug-resistant Pseudomonas aeruginosa isolates in a Thai hospital. Int J Antimicrob Agents 2013; 42 (4): 301-6
50. Shu JC, Su LH, Chia JH, et al. SHORT REPORT. Identification of a hidden outbreak due to the spread of a VIM-3-producing, extensive drug-resistant Pseudomonas aeruginosa (XDRPA) clone at a regional hospital in Taiwan. Epidemiol Infect 2013; 141 (8): 1713-16
51. Tseng SP, Tsai JC, Teng LJ, Hsueh PR. Dissemination of transposon Tn6001 in carbapenem-non-susceptible and extensively drug-resistant Pseudomonas aeruginosa in Taiwan. J Antimicrob Chemother 2009; 64 (6): 1170-4
52. Rocco M, Montini L, Alessandri E, et al. Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study. Crit Care 2013; 17 (4): R174
53. Pontikis K, Karaiskos I, Bastani S, et al. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria. Int J Antimicrob Agents 2014; 43 (1): 52-9
54. Perez F, Hujer AM, Marshall SH, et al. Extensively drug-resistant Pseudomonas aeruginosa isolates containing bla(VIM-2) and elements of salmonella genomic island 2: a new genetic resistance determinant in Northeast Ohio. Antimicrob Agent Chemother 2014; 58 (10): 5929-35
55. Dantas RC, Ferreira ML, Gontijo-Filho PP, Ribas RM. Pseudomonas aeruginosa bacteraemia: independent risk factors for mortality and impact of resistance on outcome. J Medical Microbiol 2014; 63 (Pt 12): 1679-87
56. Park YS, Lee H, Chin BS, et al. Acquisition of extensive drug-resistant Pseudomonas aeruginosa among hospitalized patients: risk factors and resistance mechanisms to carbapenems. J Hosp Infect 2011; 79 (1): 54-8
57. Willmann M, Klimek A, Vogel W, et al. Clinical and treatment-related risk factors for nosocomial colonisation with extensively drug-resistant Pseudomonas aeruginosa in a haematological patient population: a matched case control study. BMC Infect Dis 2014; 14 (1): 650
58. Samonis G, Vardakas KZ, Kofteridis DP, et al. Characteristics, risk factors and outcomes of adult cancer patients with extensively drug-resistant Pseudomonas aeruginosa infections. Infection 2014; 42 (4): 721-8
59. Keeney KM, Yurist-Doutsch S, Arrieta MC, Finlay BB. Effects of antibiotics on human microbiota and subsequent disease. Annu Rev Microbiol 2014; 68: 217-35
60. Perez-Cobas AE, Artacho A, Ott SJ, et al. Structural and functional changes in the gut microbiota associated to Clostridium difficile infection. Front Microbiol 2014; 5: 335
61. Percival SL, Suleman L, Vuotto C, Donelli G. Healthcare-Associated infections, medical devices and biofilms: risk, tolerance and control. J Med Microbiol 2015; 64 (Pt 4): 323-34
62. Bodro M, Sabe N, Tubau F, et al. Extensively drug-resistant Pseudomonas aeruginosa bacteremia in solid organ transplant recipients. Transplantation 2015; 99 (3): 616-22
63. Walker J, Moore G. Pseudomonas aeruginosa in hospital water systems: biofilms, guidelines, and practicalities. J Hosp Infect 2015; 89 (4): 324-7
64. Wendel AF, Kolbe-Busch S, Ressina S, et al. Detection and termination of an extended low-frequency hospital outbreak of GIM-1-producing Pseudomonas aeruginosa ST111 in Germany. Am J Infect Control 2015; 43 (6): 635-9
65. Willmann M, Bezdan D, Zapata L, et al. Analysis of a long-term outbreak of XDR Pseudomonas aeruginosa: a molecular epidemiological study. J Antimicrob Chemother 2015; 70 (5): 1322-30
66. Witney AA, Gould KA, Pope CF, et al. Genome sequencing and characterization of an extensively drug-resistant sequence type 111 serotype O12 hospital outbreak strain of Pseudomonas aeruginosa. Clin Microbiol Infect 2014; 20 (10): O609-18
67. Pitten FA, Panzig B, Schroder G, et al. Transmission of a multiresistant Pseudomonas aeruginosa strain at a German university hospital. J Hosp Infect 2001; 47 (2): 125-30
68. Snyder LA, Loman NJ, Faraj LA et al.Pseudomonas aeruginosa isolates from a six-year-long hospital outbreak using high-throughput whole genome sequencing. Euro Surveill 2013; 18 (42): pii: 20611
69. Valenza G, Tuschak C, Nickel S, et al. Prevalence, antimicrobial susceptibility, and genetic diversity of Pseudomonas aeruginosa as intestinal colonizer in the community. Infect Dis (Lond) 2015; 1-4. [Epub ahead of print]
70. Tacconelli E, De Angelis G, Cataldo MA, et al. Antibiotic usage and risk of colonization and infection with antibiotic-resistant bacteria: a hospital population-based study. Antimicrob Agents Chemother 2009; 53 (10): 4264-9
71. Nesher L, Rolston KV, Shah DP, et al. Fecal colonization and infection with Pseudomonas aeruginosa in recipients of allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2015; 17 (1): 33-8
72. Suarez C, Pena C, Arch O, et al. A large sustained endemic outbreak of multiresistant Pseudomonas aeruginosa: a new epidemiological scenario for nosocomial acquisition. BMC Infect Dis 2011; 11: 272
73. Pena C, Suarez C, Tubau F, et al. Nosocomial outbreak of a non-cefepime-susceptible ceftazidime-susceptible Pseudomonas aeruginosa strain overexpressing MexXY-OprM and producing an integron-borne PSE-1 betta-lactamase. J Clin Microbiol 2009; 47 (8): 2381-7
74. Vasoo S, Barreto JN, Tosh PK. Emerging issues in gram-negative bacterial resistance: an update for the practicing clinician. Mayo Clin Proc 2015; 90 (3): 395-403
75. Gould IM, Bal AM. New antibiotic agents in the pipeline and how they can help overcome microbial resistance. Virulence 2013; 4 (2): 185-91
76. Bassetti M, Merelli M, Temperoni C, Astilean A. New antibiotics for bad bugs: where are we? Ann Clin Microbiol Antimicrob 2013; 12: 22
77. Koehnke A, Friedrich RE. Antibiotic discovery in the age of structural biology-A comprehensive overview with special reference to development of drugs for the treatment of Pseudomonas aeruginosa infection. In Vivo 2015; 29 (2): 161-7
78. WHO. Antimicrobial resistance: global report on surveillance 2014. Geneva; 2014
79. Sidler JA, Frei R, Tschudin-Sutter S, et al. Is admission screening for Pseudomonas aeruginosa useful in haematologic patients? A prospective study with 1310 patients. Clin Microbiol Infect 2015; 21 (6): 572.e1-3
80. Bowers DR, Tam VH. Pseudomonas aeruginosa treatment and transmission reduction. Expert Rev Anti Infect Ther 2013; 11 (8): 831-7
81. Karaiskos I, Giamarellou H. Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches. Expert Opin Pharmacother 2014; 15 (10): 1351-70
82. Olaitan AO, Morand S, Rolain JM. Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria. Front Microbiol 2014; 5: 643
83. Taccone FS, Cotton F, Roisin S, et al. Optimal meropenem concentrations to treat multidrug-resistant Pseudomonas aeruginosa septic shock. Antimicrob Agents Chemother 2012; 56 (4): 2129-31
84. Gomez-Zorrilla S, Camoez M, Tubau F, et al. Antibiotic pressure is a major risk factor for rectal colonization by multidrug-resistant Pseudomonas aeruginosa in critically ill patients. Antimicrob Agents Chemother 2014; 58 (10): 5863-70
85. Lodise TP, Miller CD, Graves J, et al. Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance. Antimicrob Agents Chemother 2007; 51 (2): 417-22